Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 20, 2012, Pages 7859-7864

  Lee, Michelle J ^a,b   Hatton, Beryl A ^a   Villavicencio, Elisabeth H ^a,b   Khanna, Paritosh C ^b   Friedman, Seth D ^b   Ditzler, Sally ^a   Pullar, Barbara ^a   Robison, Keith ^c   White, Kerry F ^c   Tunkey, Chris ^c   LeBlanc, Michael ^a   Randolph Habecker, Julie ^a   Knoblaugh, Sue E ^a   Hansen, Stacey ^a   Richards, Andrew ^a   Wainwright, Brandon J ^d   McGovern, Karen ^c   Olson, James M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Infinity Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SARIDEGIB; VISMODEGIB;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG EFFECT; GENE MUTATION; GROWTH INHIBITION; LIFESPAN; MEDULLOBLASTOMA; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; COMPARATIVE GENOMIC HYBRIDIZATION; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MAGNETIC RESONANCE IMAGING; MEDULLOBLASTOMA; MICE; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEIN; PILOT PROJECTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, G-PROTEIN-COUPLED; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; VERATRUM ALKALOIDS;

ERINACEIDAE; MUS;

EID: 84861210533     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1114718109     Document Type: Article

References (21)

1. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A (2008) Medulloblastoma: From molecular pathology to therapy. Clin Cancer Res 14:971-976. (Pubitemid 351302541)
2. Katoh Y, Katoh M (2009) Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 9:873-886.
3. Romer JT, et al. (2004) Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/-p53-/- mice. Cancer Cell 6(3):229-240. (Pubitemid 39222036)
4. Yauch RL, et al. (2009) Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326:572-574.
5. Rudin CM, et al. (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173-1178.
6. Metcalfe C, de Sauvage FJ (2011) Hedgehog fights back: Mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 71:5057-5061.
7. Tremblay MR, et al. (2009) Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 52:4400-4418.
8. Yang Z-J, et al. (2008) Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 14(2):135-145.
9. Veiseh M, et al. (2007) Tumor paint: A chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 67:6882-6888. (Pubitemid 47105535)
10. Löscher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591-602. (Pubitemid 41059334)
11. Taipale J, et al. (2000) Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406:1005-1009.
12. Buonamici S, et al. (2010) Interfering with resistance to Smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2:51ra70.
13. Dijkgraaf GJ, et al. (2011) Small molecule inhibition of GDC-0449 refractory Smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 71: 435-444.
14. Chen JK, Taipale J, Cooper MK, Beachy PA (2002) Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 16:2743-2748. (Pubitemid 35253140)
15. Northcott PA, et al. (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414.
16. Pei Y, et al. (2012) An animal model of MYC-driven medulloblastoma. Cancer Cell 21(2):155-167.
17. Di C, et al. (2005) Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 65:919-924. (Pubitemid 40216452)
18. Adamson DC, et al. (2010) OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 70(1):181-191.
19. Bunt J, et al. (2010) Regulation of cell cycle genes and induction of senescence by overexpression of OTX2 in medulloblastoma cell lines. Mol Cancer Res 8:1344-1357.
20. Adolphe C, Hetherington R, Ellis T, Wainwright B (2006) Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res 66:2081-2088.
21. Olive KP, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461.